Semaglutide vs Tirzepatide: Weight Loss Comparison 2026

You have done the research. Both semaglutide and tirzepatide work for weight loss. The clinical trial data is strong for both. Now you need to pick one.

Short answer: tirzepatide produces greater average weight loss in clinical trials. Semaglutide is better established, more widely available as a compounded research compound, and usually cheaper. This breakdown covers exactly where each compound outperforms the other.

Talk to your doctor before starting either compound. Both have real side effect profiles and hard contraindications that matter.

How These Two Peptides Work

The core difference is receptor targeting. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve insulin sensitivity.

Tirzepatide is a dual GIP/GLP-1 agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. That second receptor is what separates tirzepatide from every prior GLP-1 compound on the market.

The GIP component appears to enhance the metabolic effects beyond what GLP-1 alone produces, and may reduce some GLP-1-induced nausea. Whether tirzepatide is actually easier to tolerate is still debated in the literature, but the superior weight loss outcomes are consistent across multiple Phase 3 trials.

Clinical Trial Results: What the Data Shows

STEP 1 (Wilding et al., NEJM 2021): Semaglutide 2.4mg weekly vs placebo in adults with obesity, no type 2 diabetes. At 68 weeks: 14.9% average body weight reduction. 86.4% of participants lost at least 5% of body weight.

SURMOUNT-1 (Jastreboff et al., NEJM 2022): Tirzepatide 5/10/15mg weekly vs placebo in adults with obesity, no type 2 diabetes. At 72 weeks, the 15mg dose achieved 20.9% average body weight reduction. 91% of participants lost at least 5% body weight.

SURPASS-2 (Frías et al., NEJM 2021): The only published direct head-to-head. Tirzepatide vs semaglutide 1mg in type 2 diabetes patients at 40 weeks. Tirzepatide 15mg: 11.2% weight reduction. Semaglutide 1mg: 8.7%. Critical caveat: semaglutide was tested at 1mg, not the 2.4mg dose used in STEP 1. No published trial compares both compounds at their maximum doses.

The 15%+ threshold is where tirzepatide's advantage becomes most pronounced. Nearly twice as many participants hit that mark on tirzepatide vs semaglutide. For people with significant weight loss goals, that gap matters.

Side Effects: What to Expect

Both compounds share the same core side effect profile: nausea, vomiting, diarrhea, constipation, and injection site reactions. These are most pronounced during dose escalation and typically improve over time.

Common effects on both compounds:

Both compounds carry the same black box warning: thyroid C-cell tumors in rodent studies. Do not use either compound if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a hard contraindication.

Some community reports suggest tirzepatide's GIP component reduces nausea at equivalent efficacy levels. Clinical evidence on tolerability differences is mixed; SURPASS-2 showed similar discontinuation rates between compounds. Individual response varies considerably.

Dosing Protocols: First 6 Months

Both compounds use slow dose escalation to minimize GI side effects. Many researchers find an effective maintenance dose below the maximum and stay there.

Semaglutide escalation (standard 2.4mg protocol):

Tirzepatide escalation (standard 15mg protocol):

Tirzepatide's escalation schedule runs 20+ weeks to reach full dose. Staying at an intermediate dose for an extra 4 weeks when GI side effects are significant is standard practice and does not reduce long-term outcomes.

Cost and Availability in 2026

Brand-name pricing without insurance: Wegovy (semaglutide 2.4mg) runs approximately $1,200-1,400 per month in the US. Zepbound (tirzepatide) runs approximately $1,000-1,200 per month. Insurance coverage is inconsistent, and prior authorization requirements remain a significant barrier for both.

Compounded versions: compounded semaglutide typically runs $150-400 per month depending on supplier and dose. Compounded tirzepatide typically runs $250-500 per month. More research peptide suppliers offer compounded semaglutide than tirzepatide, so sourcing options are broader for semaglutide.

Regulatory context: the compounding landscape for both compounds shifted significantly in 2024-2025. FDA removed semaglutide from the shortage list, affecting 503A/503B compounding eligibility. A tirzepatide compounding dispute with the FDA was resolved in 2025. Verify current compounding status before ordering, as the legal landscape continues to evolve.

Before buying from any supplier: verify batch-specific purity data from a named third-party lab. Use the COA lookup tool at peptidesrated.com/coa-lookup to cross-check batch numbers against Janoshik or Finnrick results. Never order a GLP-1 compound without documented third-party verification.

The Decision Guide

The honest assessment: if cost and availability were equal, most researchers would choose tirzepatide on weight loss outcomes alone. The 6-point gap in average body weight reduction at max dose is real and consistent across trials. But semaglutide has more long-term data, broader doctor familiarity, and is easier to source as a compounded compound in 2026.

For the full semaglutide protocol including STEP trial analysis and reconstitution walkthrough, see the complete guide at peptidesrated.com/blog/semaglutide-complete-guide.

For individual peptide pages with verified supplier comparisons, see peptidesrated.com/peptide/semaglutide and peptidesrated.com/peptide/tirzepatide.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021 (STEP 1 trial). PMID: 33567185.

2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022 (SURMOUNT-1 trial). PMID: 35658024.

3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM 2021 (SURPASS-2 trial). PMID: 34170647.

4. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes. Lancet 2021 (SURPASS-1). PMID: 33965077.

5. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin. Lancet 2021 (SURPASS-3). PMID: 34370971.

6. FDA Prescribing Information: Wegovy (semaglutide injection) 2.4 mg. Reference ID: 5241742.

7. FDA Prescribing Information: Zepbound (tirzepatide injection). Reference ID: 5448736.

Is tirzepatide stronger than semaglutide for weight loss?

In clinical trials, yes. SURMOUNT-1 showed 20.9% average weight loss at the 15mg dose vs 14.9% in the semaglutide STEP 1 trial. There is no published head-to-head trial at maximum doses for both compounds, so the cross-trial comparison is indirect. The difference is consistent across multiple studies.

Can I switch from semaglutide to tirzepatide mid-protocol?

Yes. Stop semaglutide and begin tirzepatide at the 2.5mg starting dose rather than attempting a dose-equivalent switch. GLP-1 receptor sensitivity varies between individuals, and starting tirzepatide at the bottom of the escalation schedule reduces GI side effects during the transition.

Which costs less in 2026?

Semaglutide is generally cheaper as a compounded research compound, and more suppliers carry it. For brand-name prescriptions, Wegovy and Zepbound are comparable in list price, with insurance and patient assistance programs being the primary determinant of out-of-pocket cost.

Are compounded versions as effective as brand-name?

The active molecule is the same. Compounded versions at the same dose and schedule should produce the same pharmacological effects. The variable is purity and sterility verification. Only order from suppliers with batch-specific COA data from a named third-party testing lab.

Who should not use GLP-1 receptor agonists?

Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use either compound. History of pancreatitis warrants physician consultation before use. Both compounds are contraindicated in pregnancy. Consult your doctor before starting either compound.